Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1

BACKGROUND: Maraviroc is a CC-chemokine receptor 5 antagonist approved to treat adults infected with CC-chemokine receptor 5–tropic (R5) HIV-1. Study A4001031 was conducted to evaluate the pharmacokinetics, safety and efficacy of maraviroc in combination with optimized background therapy in treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Giaquinto, Carlo, Mawela, Muthuhadini Patience, Chokephaibulkit, Kulkanya, Negra, Marinella Della, Mitha, Ismail Haroon, Fourie, Jan, Fang, Annie, van der Ryst, Elna, Valluri, Srinivas Rao, Vourvahis, Manoli, Zhang-Roper, Rebecca Yanhui, Craig, Charles, McFadyen, Lynn, Clark, Andrew, Heera, Jayvant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Williams & Wilkins 2018
Materias:
HIV Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916460/
https://www.ncbi.nlm.nih.gov/pubmed/29023357
http://dx.doi.org/10.1097/INF.0000000000001808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916460/
https://www.ncbi.nlm.nih.gov/pubmed/29023357
http://dx.doi.org/10.1097/INF.0000000000001808

Ejemplares similares